MX2019009886A - Composiciones y metodos para utilizar peptidos de neogenesis de islote y analogos de los mismos. - Google Patents

Composiciones y metodos para utilizar peptidos de neogenesis de islote y analogos de los mismos.

Info

Publication number
MX2019009886A
MX2019009886A MX2019009886A MX2019009886A MX2019009886A MX 2019009886 A MX2019009886 A MX 2019009886A MX 2019009886 A MX2019009886 A MX 2019009886A MX 2019009886 A MX2019009886 A MX 2019009886A MX 2019009886 A MX2019009886 A MX 2019009886A
Authority
MX
Mexico
Prior art keywords
analogs
peptides
methods
compositions
islet neogenesis
Prior art date
Application number
MX2019009886A
Other languages
English (en)
Inventor
Bai Ru
Liu Liping
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of MX2019009886A publication Critical patent/MX2019009886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La invención proporciona péptidos y análogos de péptidos de INGAP e HIP. Los péptidos y análogos pueden utilizarse en métodos para tratar diversas enfermedades y padecimientos. Tales enfermedades y padecimientos pueden incluir funciones pancreáticas deterioradas, tratar una enfermedad metabólica, por ejemplo, diabetes, tanto diabetes de tipo 1 como de tipo 2, inducción de islotes, expansión y proliferación para trasplante, promover neuroprotección o regeneración nerviosa, promover la regeneración hepática o inhibir la inflamación.
MX2019009886A 2013-03-15 2015-09-09 Composiciones y metodos para utilizar peptidos de neogenesis de islote y analogos de los mismos. MX2019009886A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/072771 WO2014139182A1 (en) 2013-03-15 2013-03-15 Compositions and methods of using islet neogenesis peptides and analogs thereof

Publications (1)

Publication Number Publication Date
MX2019009886A true MX2019009886A (es) 2019-10-22

Family

ID=51535856

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012038A MX2015012038A (es) 2013-03-15 2014-03-14 Composiciones y métodos para utilizar péptidos de neogénesis de islote y análogos de los mismos.
MX2019009886A MX2019009886A (es) 2013-03-15 2015-09-09 Composiciones y metodos para utilizar peptidos de neogenesis de islote y analogos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012038A MX2015012038A (es) 2013-03-15 2014-03-14 Composiciones y métodos para utilizar péptidos de neogénesis de islote y análogos de los mismos.

Country Status (14)

Country Link
US (7) US20160039877A1 (es)
EP (2) EP3473642B1 (es)
JP (2) JP6674258B2 (es)
KR (1) KR102244349B1 (es)
AU (3) AU2014231444B2 (es)
BR (1) BR112015022469A2 (es)
CA (1) CA2906240C (es)
ES (1) ES2703110T3 (es)
IL (1) IL241383B (es)
MX (2) MX2015012038A (es)
NZ (1) NZ711958A (es)
RU (1) RU2685958C2 (es)
SG (1) SG11201507404RA (es)
WO (2) WO2014139182A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4560952B2 (ja) * 1999-12-03 2010-10-13 株式会社セガ ゲーム装置及びゲームシステム
WO2014124540A1 (en) * 2013-02-15 2014-08-21 The Royal Institute For The Advancement Of Learning/Mcgill University Modified ingap peptides for treating diabetes
CN108697815A (zh) * 2016-02-10 2018-10-23 辉瑞公司 具有egfr配体的治疗性纳米颗粒及其制备和使用方法
CN108616978B (zh) * 2016-12-14 2022-04-15 中兴通讯股份有限公司 一种网络功能实体进行无状态处理的方法及装置
KR102006890B1 (ko) * 2016-12-27 2019-08-05 한양대학교 산학협력단 췌장 소도 세포 표적 펩타이드 및 이의 용도
JP7169673B2 (ja) * 2017-05-11 2022-11-11 シェンツェン ハイタイド バイオファーマシューティカル，エルティーディー． 急性膵炎の処置におけるペプチド化合物の使用
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies
CN109439612B (zh) * 2018-09-18 2021-09-21 广州领晟医疗科技有限公司 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
CN115867646A (zh) * 2020-05-01 2023-03-28 博德研究所 工程化中枢神经系统组合物
WO2023143446A1 (en) * 2022-01-25 2023-08-03 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating cytokine storm

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
FR2700011B1 (fr) 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
ATE437232T1 (de) 1993-10-25 2009-08-15 Canji Inc Rekombinanter adenoviren-vektor und verfahren zur verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5804421A (en) 1996-10-30 1998-09-08 Eastern Virginia Medical School Of The Medical College Fo Hampton Roads High level of expression of ingap in bacterial and euraryotic cells
US5935813A (en) 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020052308A1 (en) 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20040018623A1 (en) 1999-10-29 2004-01-29 Lawrence Rosenberg Medium for preparing dedifferentiated cells
US20020009730A1 (en) 1999-11-17 2002-01-24 Alex Chenchik Human stress array
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DE10056802B4 (de) 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
NZ526312A (en) 2000-12-13 2004-11-26 Borean Pharma As Combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
US20040018970A1 (en) 2000-12-19 2004-01-29 Shimkets Richard A. Novel nucleic acids and polypeptides and methods of use thereof
US20030235882A1 (en) 2000-12-19 2003-12-25 Shimkets Richard A. Novel nucleic acids and polypeptides and methods of use thereof
US6986994B2 (en) 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays
US20040158036A1 (en) 2001-03-01 2004-08-12 Lawrence Rosenberg Neuritogenic compound and uses thereof
CA2457819A1 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
CA2842429A1 (en) 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7662768B2 (en) 2002-01-11 2010-02-16 Mcgill University Transdifferentiation of pancreatic acinar cells
US7166439B2 (en) 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
WO2003094958A1 (en) 2002-05-09 2003-11-20 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
WO2004007770A2 (en) 2002-07-10 2004-01-22 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
JP2004065120A (ja) 2002-08-07 2004-03-04 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患の疾患マーカー及びその利用
AU2003270010A1 (en) 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
AU2003275853A1 (en) 2002-10-24 2004-05-13 Mcgill University Use of ingap for reversing diabetes
AU2003294828A1 (en) 2002-12-17 2004-07-09 Sinogenomax Co. Ltd. Chinese National Human Genomecenter Specific markers for pancreatic cancer
US7510708B2 (en) 2003-04-14 2009-03-31 Washington University Disruption of the REG pathway
EP1488798A1 (en) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
WO2005113812A2 (en) 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20050277593A1 (en) 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
EP1751174A4 (en) 2004-06-04 2008-07-23 Wyeth Corp PROTEIN INHIBITORS REGIII, THERAPEUTIC AGENTS AGAINST ASTHMA
KR100639677B1 (ko) 2004-11-08 2006-10-30 삼성전자주식회사 위상 및 지연 동기 루프와 이를 구비한 반도체 메모리 장치
KR100664586B1 (ko) 2004-12-22 2007-01-04 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US7393919B2 (en) * 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
US20090239796A1 (en) 2005-08-19 2009-09-24 Amylin Pharmaceuticals, Inc. Methods for treating diabetes and reducing body weight
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
US20080039393A1 (en) 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
WO2007056511A2 (en) 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
WO2007071437A2 (en) 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
WO2008011518A2 (en) 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
KR20060089873A (ko) 2006-07-25 2006-08-09 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
CA2667476A1 (en) 2006-11-02 2008-07-17 Genizon Biosciences Inc. Genemap of the human genes associated with asthma disease
WO2008064306A2 (en) * 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
FR2910311B1 (fr) 2006-12-20 2009-02-13 Oreal Composition comprenant un compose silicone et un organosilane particulier
US7923014B2 (en) 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
JP2010522762A (ja) * 2007-03-26 2010-07-08 サルトリア・フアーマシユーテイカルズ・エル・エル・シー 糖尿病の治療のための方法及びプロブコール誘導体の組成物
WO2008118946A1 (en) 2007-03-27 2008-10-02 Atherogenics, Inc. Methods and compositions using certain phenolic derivatives for the treatment of diabetes
KR20100080519A (ko) * 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
WO2009049222A1 (en) 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
US20090202475A1 (en) 2007-11-07 2009-08-13 Genentech, Inc. Compositions and methods for treatment of microbial disorders
JP2011509071A (ja) 2007-11-29 2011-03-24 ジェネンテック， インコーポレイテッド 炎症性腸疾患のための遺伝子発現マーカー
US20100004213A1 (en) 2007-11-29 2010-01-07 Abbas Alexander R Gene expression markers for inflammatory bowel disease
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
WO2009097155A1 (en) 2008-01-31 2009-08-06 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide
WO2009116861A2 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP2010085375A (ja) 2008-10-02 2010-04-15 Nationa Hospital Organization 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US8012928B2 (en) 2008-12-19 2011-09-06 The Research Foundation Of State University Of New York Truncated PAP2 and methods of making and using same
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
ES2356217B1 (es) 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
CN102686727A (zh) 2009-10-09 2012-09-19 阿纳福公司 基于c-型凝集素结构域的组合文库
WO2011043835A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
ES2374370B1 (es) 2010-08-04 2013-01-08 Universidad De Salamanca Método para la detección de daño renal.
CN102827253B (zh) * 2011-06-17 2017-07-21 上海市第一人民医院 一种抑制炎症反应的小分子多肽及其应用
WO2014124540A1 (en) * 2013-02-15 2014-08-21 The Royal Institute For The Advancement Of Learning/Mcgill University Modified ingap peptides for treating diabetes

Also Published As

Publication number Publication date
RU2015143655A3 (es) 2018-02-28
BR112015022469A2 (pt) 2017-07-18
US20160039877A1 (en) 2016-02-11
US9738695B2 (en) 2017-08-22
EP3473642A2 (en) 2019-04-24
JP7075918B2 (ja) 2022-05-26
AU2018241212B2 (en) 2020-09-17
RU2015143655A (ru) 2017-04-26
NZ711958A (en) 2020-07-31
AU2014231444A1 (en) 2015-10-01
AU2020280993A1 (en) 2021-01-07
EP3473642A3 (en) 2019-07-10
KR20160012992A (ko) 2016-02-03
CA2906240A1 (en) 2014-09-18
RU2685958C2 (ru) 2019-04-23
US20180009861A1 (en) 2018-01-11
JP2016512205A (ja) 2016-04-25
AU2018241212A1 (en) 2018-11-29
US9388215B2 (en) 2016-07-12
US20200347106A1 (en) 2020-11-05
US20220348618A1 (en) 2022-11-03
EP2970385A4 (en) 2016-12-07
US20170002049A1 (en) 2017-01-05
EP3473642B1 (en) 2022-04-13
AU2020280993B2 (en) 2022-04-21
AU2014231444B2 (en) 2018-07-19
EP2970385A1 (en) 2016-01-20
SG11201507404RA (en) 2015-10-29
IL241383B (en) 2021-03-25
MX2015012038A (es) 2016-06-02
CA2906240C (en) 2022-10-18
KR102244349B1 (ko) 2021-04-23
IL241383A0 (en) 2015-11-30
ES2703110T3 (es) 2019-03-07
WO2014139182A1 (en) 2014-09-18
EP2970385B1 (en) 2018-10-03
US20150203538A1 (en) 2015-07-23
JP6674258B2 (ja) 2020-04-01
US20190023755A1 (en) 2019-01-24
JP2020062028A (ja) 2020-04-23
WO2014139472A1 (en) 2014-09-18
US10899815B2 (en) 2021-01-26

Similar Documents

Publication Publication Date Title
MX2019009886A (es) Composiciones y metodos para utilizar peptidos de neogenesis de islote y analogos de los mismos.
PH12020550450A1 (en) Certain chemical entities, compositions and methods
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SG10201809457YA (en) Insulin receptor partial agonists
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
SG10201902872YA (en) Ex vivo proliferation of epithelial cells
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
PH12019502646A1 (en) Pyrazole magl inhibitors
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX367858B (es) Péptidos de conotoxina, composiciones farmacéuticas y usos de los mismos.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
PH12019501683A1 (en) Rorgamma modulators and uses thereof
PH12019501682A1 (en) Rorgamma modulators and uses thereof
EP3810174A4 (en) COMPOSITIONS AND METHODS FOR PROPLAGING INSULIN-PRODUCING ISLET CELLS AND THEIR THERAPEUTIC APPLICATIONS
NZ751591A (en) Compositions and methods of using islet neogenesis peptides and analogs thereof
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.